Live Breaking News & Updates on Paolo Tarantino|Page 2

Stay updated with breaking news from Paolo tarantino. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

HER2 Status May Influence Time to Next Treatment Post-Enhertu

Findings were presented at the 2023 San Antonio Breast Cancer Symposium from a study investigating real-world patients who received Enhertu for advanced breast cancer. ....

San Antonio , United States , Paolo Tarantino , Duke Cancer Center , Dana Farber Cancer Institute , Antonio Breast Cancer , Duke Cancer , Breast Cancer ,

T-DXd Demonstrates Real-World Efficacy in Advanced Breast Cancer With Dynamic HER2 Expression

Administration of fam-trastuzumab deruxtecan significantly prolonged time-to-next treatment in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course. ....

San Antonio , United States , Paolo Tarantino , Dana Farber Cancer Institute , Duke Cancer Center , Antonio Breast Cancer , Duke Cancer , Breast Cancer , Fam Trastuzumab Deruxtecan , 2023 San Antonio Breast Cancer Symposium , Her2 Positive Or Low Metastatic Breast Cancer ,

Dana-Farber Researchers to Present Findings at 2023 San Antonio Breast Cancer Symposium

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 46th annual San Antonio Breast Cancer Symposium, December 5–9, 2023. ....

San Antonio , United States , Heather Parsons , Paolo Tarantino , Nolan Priedigkeit , Trastuzumab Deruxtecan , Adrienne Waks , Sarah Sammons , Dana Farber Cancer Institute , Duke Cancer Center , San Antonio Breast Cancer Symposium , Randomized Phase , Combined With Avelumab , Metastatic Breast , Proposed Therapeutic Exploitation , Real World Activity , Metastatic Breast Cancer , Duke Cancer , Biopsy Determination , Breast Cancer , Results From , Novel Epigenomic , Cumulative Incidence ,

Dr Tarantino on the Potential Significance of SGN-B7H4V in Breast Cancer

Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer. ....

Paolo Tarantino , European Institute Of Oncology , Dana Farber Cancer Institute , European Institute , Onclive Tv , Breast Cancer , B7 H4 Vedotin , Sgn B7h4v ,

B7-H4–Directed ADCs May Broaden Breast and Gynecologic Cancer Armamentariums

Bradley J. Monk, MD, FACOG, FACS, and Paolo Tarantino, MD, discuss key data with B7-H4–directed antibody-drug conjugates across solid tumor types, the evolving role of antibody-drug conjugates in gynecologic cancers, and the importance of determining optimal sequencing with these agents in breast cancer. ....

United States , Lake Nona , San Antonio , University Of Arizona , Dana Farber Cancer Institute , Kathleen Moore , Paolo Tarantino , Cesar Perez , European Institute Of Oncology , University Of Arizona College Medicine , National Comprehensive Cancer Network , Creighton University Health Sciences Campus , Arizona College , European Institute , Sarah Cannon Research Institute , Florida Cancer Specialists , Antonio Breast Cancer Symposium , B7 H4 , Gynecologic Cancers , Breast Cancer , Sgnb7h4v 001 Trial ,